TY - JOUR
T1 - Updates to the management of kidney cancer
AU - Jonasch, Eric
N1 - Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
AB - Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
UR - http://www.scopus.com/inward/record.url?scp=85048280279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048280279&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0039
DO - 10.6004/jnccn.2018.0039
M3 - Article
C2 - 29784745
AN - SCOPUS:85048280279
SN - 1540-1405
VL - 16
SP - 639
EP - 641
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5S
ER -